<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Approach to the patient with retiform (angulated) purpura
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Approach to the patient with retiform (angulated) purpura
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Approach to the patient with retiform (angulated) purpura
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Kelly, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Erik Stratman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 24, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H429795">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Purpura are nonblanchable, hemorrhagic skin lesions that result from the leakage of red blood cells into the skin. The term "retiform purpura" describes lesions that demonstrate an angulated or branched configuration  (
         <a class="graphic graphic_picture graphicRef53920 graphicRef61719 graphicRef65011" href="/z/d/graphic/53920.html" rel="external">
          picture 1A-C
         </a>
         ). Retiform purpura can occur in a variety of disorders; thus, identifying the underlying cause is an important component of patient management.
        </p>
        <p>
         The potential causes of retiform purpura and the approach to the assessment of patients with these lesions will be reviewed here. Additional details on the pathogenesis, clinical manifestations, and treatment of disorders that present with retiform purpura are discussed elsewhere in UpToDate. (See
         <a class="local">
          'Associated disorders'
         </a>
         below.)
        </p>
        <p>
         Cutaneous vasculitis, a potential cause of purpura (including retiform purpura), is reviewed in greater detail separately. The differential diagnosis of purpura in children is also reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/8241.html" rel="external">
          "Overview of cutaneous small vessel vasculitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">
          "Evaluation of adults with cutaneous lesions of vasculitis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6443.html" rel="external">
          "Purpuric skin lesions (petechiae, purpura, and ecchymoses) in children: Evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2323759615">
         <span class="h1">
          CLINICAL FINDINGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retiform purpura are nonblanchable, persistent, dark red to dark purple, hemorrhagic patches or plaques that occur on the skin and exhibit a characteristic branched configuration  (
         <a class="graphic graphic_picture graphicRef53920" href="/z/d/graphic/53920.html" rel="external">
          picture 1A
         </a>
         ). Lesions may be relatively small (eg, 1 to 2 cm) or more than 10 cm in diameter and may be limited to a focal area of skin, particular body region, or widespread  (
         <a class="graphic graphic_picture graphicRef65890 graphicRef61719 graphicRef57103" href="/z/d/graphic/65890.html" rel="external">
          picture 1B, 1D-E
         </a>
         ). Widespread retiform purpura, termed "purpura fulminans," can represent a life-threatening condition. (See
         <a class="local">
          'Recognition of life-threatening emergencies'
         </a>
         below.)
        </p>
        <p>
         Prominent, peripheral erythema may occur in lesions that develop secondary to inflammatory processes and areas of necrosis due to tissue infarction may be present  (
         <a class="graphic graphic_picture graphicRef66308" href="/z/d/graphic/66308.html" rel="external">
          picture 2
         </a>
         ). Pain within lesions is common and may be severe.
        </p>
        <p class="headingAnchor" id="H1710842826">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retiform purpura develop as a consequence of complete vascular occlusion and vascular damage involving blood vessels in the skin. Lesions may occur in the setting of intravascular abnormalities in which thrombi, proteins, or emboli obstruct cutaneous vessels, or may involve direct damage to vessel walls, as occurs in vasculitis, calciphylaxis, and some severe opportunistic infections.
        </p>
        <p>
         As in livedo reticularis  (
         <a class="graphic graphic_picture graphicRef79545 graphicRef61842" href="/z/d/graphic/79545.html" rel="external">
          picture 3A-B
         </a>
         ) and livedo racemosa  (
         <a class="graphic graphic_picture graphicRef64023" href="/z/d/graphic/64023.html" rel="external">
          picture 4
         </a>
         ) (additional disorders associated with vasculopathy or vasculitis), the angulated or branched shape of retiform purpura reflects the vascular architecture in the skin (see
         <a class="local">
          'Differential diagnosis'
         </a>
         below). The hemorrhagic appearance of purpura results from the local extravasation of red blood cells. Skin necrosis results from infarction.
        </p>
        <p class="headingAnchor" id="H425705">
         <span class="h1">
          ASSOCIATED DISORDERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple vasculopathic disorders may present with retiform purpura [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H933744">
         <span class="h2">
          Intravascular abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thrombosis, intravascular deposition of abnormal proteins, and embolic phenomena may result in the development of retiform purpura.
        </p>
        <p class="headingAnchor" id="H933761">
         <span class="h3">
          Thrombotic and coagulopathic disorders
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disseminated intravascular coagulation (DIC)
         </strong>
         – DIC may occur in the setting of sepsis, organ failure, trauma, malignancy, and other severe disorders, such as homozygous protein C deficiency in neonates. Patients with DIC exhibit clinical manifestations of both hemorrhage and thrombosis. Purpura may be widespread (
         <strong>
          purpura fulminans
         </strong>
         ), and the disorder can be fatal
         <strong>
         </strong>
         (
         <a class="graphic graphic_picture graphicRef61719 graphicRef74453" href="/z/d/graphic/61719.html" rel="external">
          picture 1B, 1F
         </a>
         ) [
         <a href="#rid2">
          2,3
         </a>
         ]. Meningococcemia is a common cause of DIC. (See
         <a class="local">
          'Recognition of life-threatening emergencies'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5915.html" rel="external">
          "Disseminated intravascular coagulation in infants and children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypercoagulable states
         </strong>
         – Hypercoagulable states, such as antiphospholipid syndrome, may lead to retiform purpura. The mechanisms through which antiphospholipid antibodies in serum lead to thrombosis are not completely understood  (
         <a class="graphic graphic_picture graphicRef65011 graphicRef65890" href="/z/d/graphic/65011.html" rel="external">
          picture 1C-D
         </a>
         ). Common additional features of antiphospholipid syndrome include livedo reticularis, livedo racemosa, cutaneous infarctions or ulceration, recurrent venous or arterial thromboses, and fetal loss [
         <a href="#rid4">
          4-7
         </a>
         ]. Examples of other hypercoagulable states that may present with retiform purpura include antithrombin III deficiency, protein C/S deficiency, prothrombin III mutation, factor V Leiden, and hyperhomocysteinemia [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">
          "Clinical manifestations of antiphospholipid syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4678.html" rel="external">
          "Diagnosis of antiphospholipid syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombotic thrombocytopenic purpura (TTP)
         </strong>
         – TTP is a rare, idiopathic disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, neurologic abnormalities, and renal disease [
         <a href="#rid8">
          8,9
         </a>
         ]. Nonretiform purpura related to thrombocytopenia are often present. (See
         <a class="medical medical_review" href="/z/d/html/1338.html" rel="external">
          "Diagnosis of immune TTP"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Warfarin
         </strong>
         <strong>
          -induced skin necrosis
         </strong>
         – This condition results from the development of a transient, hypercoagulable state secondary to warfarin-induced reduction of protein C (an anticoagulant) early in the course of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         therapy. Purpura are extensive and demonstrate a predilection for areas with significant adipose tissue (eg, thighs, buttocks, abdomen, breasts  (
         <a class="graphic graphic_picture graphicRef51999 graphicRef62792 graphicRef80462" href="/z/d/graphic/51999.html" rel="external">
          picture 5A-C
         </a>
         )). Patients with underlying protein C deficiency are at increased risk for this disorder [
         <a href="#rid10">
          10-12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1354.html" rel="external">
          "Protein C deficiency", section on 'Warfarin-induced skin necrosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heparin-induced thrombocytopenia
         </strong>
         –
         <strong>
         </strong>
         Heparin-induced thrombocytopenia is an immune-mediated disorder that usually occurs 5 to 10 days after treatment with heparin [
         <a href="#rid13">
          13,14
         </a>
         ]. Necrotic, purpuric lesions may occur at sites of subcutaneous heparin injection or in areas distant from the site of administration (heparin necrosis). Patients may also exhibit large vessel venous or arterial thromboses
         <strong>
         </strong>
         [
         <a href="#rid13">
          13,14
         </a>
         ]
         <strong>
         </strong>
         (see
         <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">
          "Management of heparin-induced thrombocytopenia"
         </a>
         ). Heparin necrosis may also occur in the absence of thrombocytopenia  (
         <a class="graphic graphic_picture graphicRef63715 graphicRef71259" href="/z/d/graphic/63715.html" rel="external">
          picture 6A-B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paroxysmal nocturnal hemoglobinuria
         </strong>
         – This rare disorder due to a defect in the
         <em>
          PIG-A
         </em>
         gene is characterized by venous thrombosis and hemolysis, resulting in hemoglobinuria. In addition to retiform purpura, patients may present with bullae, petechiae, or ulcerations. (See
         <a class="medical medical_review" href="/z/d/html/7159.html" rel="external">
          "Clinical manifestations and diagnosis of paroxysmal nocturnal hemoglobinuria"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7163.html" rel="external">
          "Treatment and prognosis of paroxysmal nocturnal hemoglobinuria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H933953">
         <span class="h3">
          Intravascular protein deposition
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cryoglobulinemia (type I)
         </strong>
         – In type 1 cryoglobulinemia, retiform purpura develop in the setting of blood hyperviscosity and blood vessel occlusion due to the precipitation of immunoglobulins in response to cold. Lesions are often found on acral areas; livedo reticularis, acrocyanosis, and infarction may also be present  (
         <a class="graphic graphic_picture graphicRef104189" href="/z/d/graphic/104189.html" rel="external">
          picture 7
         </a>
         ) [
         <a href="#rid15">
          15,16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cryofibrinogenemia
         </strong>
         – Cryofibrinogenemia results from the precipitation of fibrin, fibrinogen, and/or fibronectin in plasma during cold exposure. Like cryoglobulinemia, retiform purpura are often acral. Additional findings may include livedo reticularis, livedo racemosa, and painful ulcerations [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">
          "Disorders of fibrinogen", section on 'Cryofibrinogenemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Paraproteinemia
         </strong>
         – Rarely, paraproteinemia induces blood hyperviscosity and plugging of vessels, resulting in the development of retiform purpura [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H933961">
         <span class="h3">
          Embolic disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Embolic disorders that may lead to retiform purpura include cholesterol emboli, septic emboli, atrial myxoma, and other disorders:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cholesterol emboli
         </strong>
         – Retiform purpura associated with cholesterol embolization are often located on the distal lower extremities  (
         <a class="graphic graphic_picture graphicRef123032 graphicRef69150" href="/z/d/graphic/123032.html" rel="external">
          picture 8A-B
         </a>
         ). Other cutaneous features include livedo reticularis, livedo racemosa, gangrene, cutaneous infarction, ulceration, and cyanosis (blue toe syndrome)  (
         <a class="graphic graphic_picture graphicRef58761" href="/z/d/graphic/58761.html" rel="external">
          picture 9
         </a>
         ). Renal, gastrointestinal, ocular, or central nervous system abnormalities may also occur. Many patients exhibit eosinophilia [
         <a href="#rid19">
          19,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8184.html" rel="external">
          "Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Septic emboli
         </strong>
         – Purpura due to septic emboli most commonly occur in the setting of infectious endocarditis but may also occur in other forms of septicemia. Lesions are typically acral. Other cutaneous findings, such as petechiae or Janeway lesions, may be present. (See
         <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">
          "Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atrial myxoma
         </strong>
         – Atrial myxomas are benign tumors of the heart. Tumor fragments may embolize systemically, and patients often exhibit constitutional symptoms (eg, fever, weight loss) [
         <a href="#rid21">
          21,22
         </a>
         ]. As with other embolic phenomena, lesions are often acral. (See
         <a class="medical medical_review" href="/z/d/html/4881.html" rel="external">
          "Cardiac tumors", section on 'Myxomas'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         –
         <strong>
         </strong>
         Emboli resulting in vessel occlusion and retiform purpura may also occur in nonbacterial thrombotic endocarditis (marantic endocarditis, Libman-Sacks endocarditis) and hypereosinophilic syndrome. (See
         <a class="medical medical_review" href="/z/d/html/91781.html" rel="external">
          "Nonbacterial thrombotic endocarditis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">
          "Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H933969">
         <span class="h2">
          Vessel wall pathology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Damage to vessel walls resulting in retiform purpura may occur in vasculitis, various opportunistic infections, calciphylaxis, and primary hyperoxaluria:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vasculitis
         </strong>
         – Vasculitis is defined by the presence of an inflammatory infiltrate invading blood vessel walls and fibrinoid necrosis (fibrin deposition within vessel walls or lumina). Retiform purpura are classically seen in vasculitides that affect medium-sized cutaneous vessels. In contrast, small vessel vasculitis most often presents with nonretiform palpable purpura. (See
         <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">
          "Evaluation of adults with cutaneous lesions of vasculitis", section on 'Diagnostic criteria'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">
          "Evaluation of adults with cutaneous lesions of vasculitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Examples of vasculitides that may present with retiform purpura include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Septic vasculitis
         </strong>
         – Vasculitis presenting with retiform purpura may occur in meningococcemia, gonococcemia, pseudomonal or streptococcal septicemia, rickettsial infections, infective endocarditis, and other infectious states [
         <a href="#rid23">
          23-25
         </a>
         ]. In the setting of severe infection, retiform purpura may also result from DIC. (See
         <a class="medical medical_review" href="/z/d/html/1300.html" rel="external">
          "Clinical manifestations of meningococcal infection"
         </a>
         and
         <a class="local">
          'Recognition of life-threatening emergencies'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Vasculitis related to autoimmune disease or primary systemic vasculitis
         </strong>
         (eg, rheumatoid arthritis, systemic lupus erythematosus, cutaneous or systemic polyarteritis nodosa, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis [Churg-Strauss]). (See
         <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">
          "Evaluation of adults with cutaneous lesions of vasculitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cryoglobulinemic vasculitis (cryoglobulinemia types 2 and 3)
         </strong>
         [
         <a href="#rid15">
          15,26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3062.html" rel="external">
          "Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Opportunistic infections
         </strong>
         –
         <strong>
         </strong>
         In immunocompromised patients, invasion of infectious organisms into blood vessel walls and lumina may result in vessel occlusion and the development of retiform purpura. This phenomenon may be seen in association with pseudomonal infection (ecthyma gangrenosum  (
         <a class="graphic graphic_picture graphicRef53544" href="/z/d/graphic/53544.html" rel="external">
          picture 10
         </a>
         )), invasive fungal infections (eg, mucormycosis, aspergillosis, candidiasis), disseminated strongyloidiasis, and in lepromatous leprosy as a feature of the Lucio phenomenon.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7643.html" rel="external">
          "Pseudomonas aeruginosa skin and soft tissue infections", section on 'Ecthyma Gangrenosum'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">
          "Mucormycosis (zygomycosis)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">
          "Epidemiology and clinical manifestations of invasive aspergillosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">
          "Strongyloidiasis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5348.html" rel="external">
          "Leprosy: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Type 2 reaction (T2R, erythema nodosum leprosum, ENL)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Calciphylaxis
         </strong>
         – Calciphylaxis is a life-threatening disorder characterized by the deposition of calcium in blood vessels  (
         <a class="graphic graphic_picture graphicRef66308" href="/z/d/graphic/66308.html" rel="external">
          picture 2
         </a>
         ). This condition almost always occurs in the setting of advanced, chronic renal failure. Extremely painful retiform purpura may develop; lesions frequently occur in adipose-rich areas, such as the buttocks, abdomen, or thighs. Other cutaneous features include livedo reticularis, livedo racemosa, and cutaneous infarction [
         <a href="#rid27">
          27,28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1944.html" rel="external">
          "Calciphylaxis (calcific uremic arteriolopathy)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Primary hyperoxaluria
         </strong>
         – Primary hyperoxaluria is a rare, autosomal recessive, metabolic disorder that results in the overproduction of oxalate. Patients develop renal stones and calcium oxalate deposits in multiple tissues, including blood vessels [
         <a href="#rid29">
          29,30
         </a>
         ]. The cutaneous lesions of primary hyperoxaluria are similar to calciphylaxis. (See
         <a class="medical medical_review" href="/z/d/html/6141.html" rel="external">
          "Primary hyperoxaluria"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4167726516">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examples of other conditions that may present with retiform purpura include livedoid vasculopathy, pyoderma gangrenosum, and vasculopathy or vasculitis due to levamisole-contaminated cocaine:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Livedoid vasculopathy
         </strong>
         –
         <strong>
         </strong>
         Livedoid vasculopathy (also known as atrophie blanche) is a cutaneous disease characterized by the development of fibrin thrombi in cutaneous vessels. The condition typically manifests as recurrent, small, purpuric, ulcerative lesions on the distal lower extremities  (
         <a class="graphic graphic_picture graphicRef52262" href="/z/d/graphic/52262.html" rel="external">
          picture 11
         </a>
         ). Pale scars with stippled telangiectasia are left after healing [
         <a href="#rid31">
          31-33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4684.html" rel="external">
          "Livedoid vasculopathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pyoderma gangrenosum
         </strong>
         – Pyoderma gangrenosum is an inflammatory skin disorder that typically presents with ulceration. Infrequently, it may present with retiform purpura that evolve into ulcers that exhibit the violaceous edges classically seen in this disorder. Pyoderma gangrenosum may occur in association with inflammatory bowel disease, inflammatory arthritis, or hematologic malignancies [
         <a href="#rid34">
          34-36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13782.html" rel="external">
          "Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombotic vasculopathy or vasculitis due to
         </strong>
         <strong>
          levamisole
         </strong>
         <strong>
          -contaminated cocaine
         </strong>
         –
         <strong>
         </strong>
         Use of cocaine contaminated with levamisole has been associated with the development of tender purpura on the ears and necrotic, retiform purpura on the trunk or extremities  (
         <a class="graphic graphic_picture graphicRef74436 graphicRef77067 graphicRef55590" href="/z/d/graphic/74436.html" rel="external">
          picture 12A-C
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/303.html" rel="external">
          "Cocaine: Acute intoxication", section on 'Levamisole'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H958061844">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retiform purpura must be distinguished from nonpurpuric skin disorders that may exhibit a branched configuration, such as livedo reticularis and livedo racemosa, as well as other types of purpuric lesions.
        </p>
        <p>
         Livedo reticularis and livedo racemosa are nonpurpuric disorders that present with accentuated vascular patterns in the skin. Livedo reticularis, which results from the slowing of blood flow through cutaneous vessels, presents as a blanchable, reticulated vascular pattern with a red-blue or violaceous hue  (
         <a class="graphic graphic_picture graphicRef79545 graphicRef61842" href="/z/d/graphic/79545.html" rel="external">
          picture 3A-B
         </a>
         ). Livedo racemosa, which develops in the setting of irregular impairment of blood flow, is characterized by a more abrupt, patchy, and broken vascular pattern with or without areas of necrosis  (
         <a class="graphic graphic_picture graphicRef64023" href="/z/d/graphic/64023.html" rel="external">
          picture 4
         </a>
         ). In some conditions, retiform purpura may coexist with livedo reticularis or livedo racemosa. (See
         <a class="local">
          'Associated disorders'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">
          "Evaluation of adults with cutaneous lesions of vasculitis", section on 'When to suspect cutaneous vasculitis'
         </a>
         .)
        </p>
        <p>
         The configuration of retiform purpura distinguishes these lesions from petechiae and purpura due to trauma or bleeding diatheses. Such lesions typically lack the angulated shape of retiform purpura  (
         <a class="graphic graphic_picture graphicRef76671 graphicRef70793" href="/z/d/graphic/76671.html" rel="external">
          picture 13A-B
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H425712">
         <span class="h1">
          PATIENT ASSESSMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The assessment of patients with retiform purpura focuses on early recognition of patients with acute, life-threatening disease that requires immediate intervention and the detection of the underlying cause of purpura formation [
         <a href="#rid1">
          1
         </a>
         ]. In general, the evaluation should include at least a patient history, physical examination, skin biopsy, and select laboratory tests. The need for additional microbiologic and radiologic testing is based upon the clinical presentation.
        </p>
        <p class="headingAnchor" id="H136707379">
         <span class="h2">
          Recognition of life-threatening emergencies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examples of acute and immediately life-threatening conditions that may present with retiform purpura include disseminated intravascular coagulation (DIC; a disorder that may occur due to sepsis, trauma, malignancy, obstetric emergencies, neonatal homozygous C deficiency, or other causes) and opportunistic infections. Mortality from these conditions can be high, and prompt evaluation is necessary for these patients.
        </p>
        <p>
         Findings that should prompt investigation for these disorders include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Purpura fulminans (acute development of widespread retiform purpura  (
         <a class="graphic graphic_picture graphicRef57103 graphicRef53920 graphicRef52107" href="/z/d/graphic/57103.html" rel="external">
          picture 1A, 1E, 1G
         </a>
         ))
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Signs or symptoms of sepsis and/or shock
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other signs of severe illness (fever, organ failure, altered mental status)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute development of retiform purpura in an immunocompromised patient
        </p>
        <p>
        </p>
        <p>
         Immediate initial tests for such patients should include [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count with differential
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Comprehensive metabolic panel
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urgent skin biopsy (see
         <a class="local">
          'Skin biopsy'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Erythrocyte sedimentation rate and/or C-reactive protein level
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urine toxicology
        </p>
        <p>
        </p>
        <p>
         In addition, the presence of purpura fulminans should prompt:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory evaluation for DIC (see
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Diagnostic evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5915.html" rel="external">
          "Disseminated intravascular coagulation in infants and children", section on 'Diagnosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         There should be a high suspicion for infection in patients with purpura fulminans or with signs of sepsis and in immunocompromised patients with retiform purpura. The initial evaluation of these patients should include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lesional punch biopsy for tissue culture (see
         <a class="local">
          'Assessment for infection'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation for sepsis (cultures [blood and other suspected sites of infection], blood tests, and radiologic imaging, as indicated) and consideration of broad-spectrum antibiotic and antifungal coverage while awaiting results
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1613.html" rel="external">
          "Evaluation and management of suspected sepsis and septic shock in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6395.html" rel="external">
          "Sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tests for specific suspected infections (eg, invasive aspergillosis)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H425719">
         <span class="h2">
          Patient history
         </span>
         <span class="headingEndMark">
          —
         </span>
         The medical history should be obtained with particular emphasis on factors that may assist with the identification of the underlying disorder, such as:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms of infection
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of thrombotic disease, which may suggest antiphospholipid syndrome or genetic disorders characterized by hypercoagulability:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Deep venous thromboses or pulmonary emboli
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Recurrent, spontaneous abortions
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Family history of thrombotic events
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug history, which may suggest warfarin-induced skin necrosis, heparin-induced thrombocytopenia, or vasculopathy or vasculitis due to levamisole-contaminated cocaine
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of organ dysfunction:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Renal failure, which may suggest calciphylaxis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of heart murmur or valve dysfunction, which may suggest endocarditis or atrial myxoma
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of myeloproliferative conditions and blood dyscrasias, which may suggest occlusion related to blood hyperviscosity
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of hyperlipidemia, ischemic heart disease, or peripheral vascular disease, which may suggest atheroemboli
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of or symptoms of connective tissue disease or primary systemic vasculitis, which may suggest vasculitis related to rheumatoid arthritis, systemic lupus erythematosus, polyarteritis nodosa, granulomatosis with polyangiitis, or eosinophilic granulomatosis with polyangiitis (EGPA; Churg-Strauss)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exacerbation of lesions with cold exposure, which may suggest cryoglobulinemia or cryofibrinogenemia
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H425726">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         A full physical examination and skin examination should be performed. The examination confirms that the cutaneous findings are consistent with retiform purpura and allows for the detection of features suggestive of an underlying cause. In particular, the skin examination should assess the appearance, palpability, and distribution of purpuric lesions, as well as the presence of other cutaneous findings.
        </p>
        <p class="headingAnchor" id="H428237">
         <span class="h3">
          Lesion color and palpability
         </span>
         <span class="headingEndMark">
          —
         </span>
         Retiform purpura are typically dark red to dark purple, and unlike erythema associated with nonpurpuric, inflammatory skin disorders, the color of purpura fails to blanch under pressure. Diascopy (application of pressure to a lesion with a glass slide) can be used to confirm the nonblanchable nature of a purpuric lesion.
        </p>
        <p>
         In some cases, early lesions demonstrate significant erythema, which suggests the presence of a primary inflammatory process [
         <a href="#rid37">
          37
         </a>
         ]. These inflammatory lesions are frequently palpable and may appear in the following conditions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vasculitis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Livedoid vasculopathy
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pyoderma gangrenosum
        </p>
        <p>
        </p>
        <p>
         Retiform purpura associated with noninflammatory, intravascular, occlusive vasculopathies may be palpable or macular but typically lack prominent erythema. (See
         <a class="local">
          'Intravascular abnormalities'
         </a>
         above.)
        </p>
        <p>
         Areas of necrosis due to tissue infarction may occur in both noninflammatory and inflammatory lesions.
        </p>
        <p>
         With time and the breakdown of extravasated hemoglobin, purpura may develop a greenish or yellow-brown color.
        </p>
        <p class="headingAnchor" id="H428245">
         <span class="h3">
          Lesion distribution
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical distribution of lesions may assist in diagnosis  (
         <a class="graphic graphic_table graphicRef123034" href="/z/d/graphic/123034.html" rel="external">
          table 1
         </a>
         ). As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retiform purpura in areas with significant adipose tissue, such as the buttocks, thighs, and abdomen, may occur in warfarin-induced skin necrosis or calciphylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retiform purpura predominantly involving lower extremities may occur in vasculitis, livedoid vasculopathy, cholesterol emboli, or calciphylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Retiform purpura primarily involving acral areas may occur in septic vasculitis, embolic disorders, cryoglobulinemia, or cryofibrinogenemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Widespread, extensive purpura (purpura fulminans) may occur in infection, DIC, or warfarin-induced skin necrosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of unilateral lesions may suggest embolic phenomena.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H428253">
         <span class="h3">
          Associated physical findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of additional cutaneous or extracutaneous findings should be assessed. As examples, the detection of a heart murmur, splinter hemorrhages  (
         <a class="graphic graphic_picture graphicRef72076" href="/z/d/graphic/72076.html" rel="external">
          picture 14
         </a>
         ), Osler nodes  (
         <a class="graphic graphic_picture graphicRef68796" href="/z/d/graphic/68796.html" rel="external">
          picture 15
         </a>
         ), or Janeway lesions  (
         <a class="graphic graphic_picture graphicRef58380" href="/z/d/graphic/58380.html" rel="external">
          picture 16
         </a>
         ) suggests infectious endocarditis, and respiratory symptoms may occur in patients with EGPA or granulomatosis with polyangiitis  (
         <a class="graphic graphic_table graphicRef123036" href="/z/d/graphic/123036.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         The detection of additional cutaneous findings may also assist with diagnosis. As an example, livedo reticularis  (
         <a class="graphic graphic_picture graphicRef79545 graphicRef61842" href="/z/d/graphic/79545.html" rel="external">
          picture 3A-B
         </a>
         ) is a common feature of several disorders that may present with retiform purpura, such as antiphospholipid antibody syndrome, polyarteritis nodosa, cholesterol emboli, and cryoglobulinemia.
        </p>
        <p class="headingAnchor" id="H426722">
         <span class="h2">
          Skin biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin biopsies offer insight into the pathogenic mechanism of retiform purpura and, therefore, can be useful for diagnosis. We advocate the performance of skin biopsies in most patients.
        </p>
        <p class="headingAnchor" id="H428261">
         <span class="h3">
          Type and location of biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluation of vessels in the dermis and subcutis is important in retiform purpura. Thus, punch or incisional wedge biopsies are performed, rather than more superficial shave biopsies. (See
         <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">
          "Skin biopsy techniques"
         </a>
         .)
        </p>
        <p>
         Preferred sites for biopsies for histopathologic examination include areas that are painful or tender; biopsying both from the center and the edge of a lesion may also increase the diagnostic yield [
         <a href="#rid38">
          38
         </a>
         ]. Areas of frank necrosis or ulceration should be
         <strong>
          avoided
         </strong>
         , since necrotic tissue may fail to demonstrate diagnostic histopathologic findings. In addition, biopsies of necrotic areas may demonstrate an inflammatory response resembling primary vasculitis in patients with nonvasculitic disorders [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         The approach to biopsies for tissue culture for patients with findings suggestive of infection differs. (See
         <a class="local">
          'Assessment for infection'
         </a>
         below.)
        </p>
        <p>
         Vasculitis is a common cause of inflammatory retiform purpura. The approach to the biopsy of lesions that are suspicious for vasculitis is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">
          "Evaluation of adults with cutaneous lesions of vasculitis", section on 'Skin biopsy to confirm vasculitis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H428268">
         <span class="h3">
          Assessment of biopsy results
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several histopathologic patterns are associated with retiform purpura; a table correlating histopathologic findings with specific disorders is provided  (
         <a class="graphic graphic_table graphicRef77042" href="/z/d/graphic/77042.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1323398098">
         <span class="h3">
          Assessment for infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         When infection is suspected, a tissue specimen should also be sent for culture. A punch biopsy from the center of a retiform purpura lesion that shows early signs of necrosis is ideal [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Other techniques that may be helpful for assessing for infection include aspiration and culture of fluid within hemorrhagic bullae, scraping of the roof of bullae for potassium hydroxide preparations, and smearing of tissue specimens on a glass slide for a touch preparations [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5562.html" rel="external">
          "Office-based dermatologic diagnostic procedures", section on 'Potassium hydroxide preparation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H426729">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine initial laboratory studies for the stable patient with noninflammatory retiform purpura include [
         <a href="#rid37">
          37
         </a>
         ] (see
         <a class="local">
          'Intravascular abnormalities'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count with platelets and differential
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood smear
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Partial thromboplastin time
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatic and renal function tests
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cryoglobulins in patients with lesions and symptoms suggestive of this disorder (eg, acral lesions exacerbated by cold exposure) (see
         <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">
          "Overview of cryoglobulins and cryoglobulinemia", section on 'Detection of cryoglobulins'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antineutrophil cytoplasmic antibodies
        </p>
        <p>
        </p>
        <p>
         The diagnostic utility of these laboratory studies is described in a table  (
         <a class="graphic graphic_table graphicRef62872" href="/z/d/graphic/62872.html" rel="external">
          table 4
         </a>
         ). Additional tests may be ordered based upon the results of these studies, skin biopsy findings, and suspicion of the underlying disorder. In cases in which infection is suspected, blood and/or urine cultures should be obtained.
        </p>
        <p>
         Patients with noninflammatory, nonvasculitic retiform purpura in whom a thrombotic disorder is suspected (eg, with a personal history or strong family history of venous thromboembolism and/or other findings suggestive of these disorders) may benefit from testing for antiphospholipid syndrome and inheritable thrombophilias. (See
         <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">
          "Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors", section on 'Patient selection for additional testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1363.html" rel="external">
          "Evaluating adult patients with established venous thromboembolism for acquired and inherited risk factors", section on 'Hypercoagulable tests'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5920.html" rel="external">
          "Thrombophilia testing in children and adolescents", section on 'Approach to thrombophilia testing'
         </a>
         .)
        </p>
        <p>
         Patients with inflammatory retiform purpura should be evaluated for the possibility of vasculitis. (See
         <a class="local">
          'Lesion color and palpability'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">
          "Evaluation of adults with cutaneous lesions of vasculitis"
         </a>
         .)
        </p>
        <p>
         Patients with purpura fulminans require assessment for DIC. (See
         <a class="local">
          'Recognition of life-threatening emergencies'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Diagnostic evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5915.html" rel="external">
          "Disseminated intravascular coagulation in infants and children", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8555553">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of retiform purpura is dependent upon correction of the underlying etiology. (See
         <a class="local">
          'Associated disorders'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H12657719">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical findings
         </strong>
         – Retiform purpura are hemorrhagic skin lesions characterized by an angulated or branched appearance  (
         <a class="graphic graphic_picture graphicRef53920 graphicRef61719 graphicRef65011" href="/z/d/graphic/53920.html" rel="external">
          picture 1A-C
         </a>
         ). The shape of retiform purpura is reflective of the pattern of the underlying vascular network. (See
         <a class="local">
          'Clinical findings'
         </a>
         above and
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – Retiform purpura occur as a consequence of disrupted vascular flow in the skin or subcutis. Disorders that cause vessel occlusion through thrombosis, intravascular protein deposition, emboli, or vessel wall destruction are associated with the development of these lesions  (
         <a class="graphic graphic_table graphicRef123036" href="/z/d/graphic/123036.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Life-threatening presentations
         </strong>
         – The acute appearance of extensive purpura, termed "purpura fulminans," is a life-threatening disorder that occurs in the setting of disseminated intravascular coagulation (DIC). Identification of the underlying cause of DIC is essential for management. Retiform purpura may also occur in the setting of life-threatening, opportunistic infections. Prompt evaluation of patients with purpura fulminans, with signs of sepsis or severe illness, or in immunocompromised states is essential. (See
         <a class="local">
          'Recognition of life-threatening emergencies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient assessment
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          History and physical examination
         </strong>
         – A thorough history and physical examination may provide valuable clues for diagnosis and should be performed in all patients who present with retiform purpura. The skin examination should include assessment of the color and distribution of purpura  (
         <a class="graphic graphic_table graphicRef123034" href="/z/d/graphic/123034.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Patient assessment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Skin biopsy
         </strong>
         – Skin biopsies of retiform purpura can provide useful diagnostic information  (
         <a class="graphic graphic_table graphicRef77042" href="/z/d/graphic/77042.html" rel="external">
          table 3
         </a>
         ). We perform a skin biopsy in almost all patients. A punch or excisional wedge biopsy should be performed to allow for adequate evaluation of vessels in the dermis and subcutis. Areas of necrosis should be avoided. A tissue culture should be performed if infection is suspected. (See
         <a class="local">
          'Skin biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory tests
         </strong>
         – An appropriate initial laboratory workup for stable patients with noninflammatory retiform purpura includes a complete blood count with differential and platelets, blood smear, partial thromboplastin time, hepatic and renal function tests, cryoglobulins in patients with acral lesions exacerbated by cold exposure, and antineutrophil cytoplasmic antibodies  (
         <a class="graphic graphic_table graphicRef62872" href="/z/d/graphic/62872.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Additional tests may be added based upon these results, skin biopsy findings, and the likelihood of specific disorders. If infection is suspected, blood, tissue, and/or tissue cultures should be performed. (See
         <a class="local">
          'Laboratory tests'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Georgesen C, Fox LP, Harp J. Retiform purpura: A diagnostic approach. J Am Acad Dermatol 2020; 82:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol 2004; 124:567.
          </a>
         </li>
         <li class="breakAll">
          Harris EN. Antiphospholipid syndrome. In: Rheumatology, 2nd ed, Klippel JH, Dieppe PA (Eds), Mosby, London 1998. p.7.35.1.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006; 295:1050.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erkan D, Lockshin MD. New treatments for antiphospholipid syndrome. Rheum Dis Clin North Am 2006; 32:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lau DH, Wun T. Early manifestation of thrombotic thrombocytopenic purpura. Am J Med 1993; 95:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bouw MC, Dors N, van Ommen H, Ramakers-van Woerden NL. Thrombotic thrombocytopenic purpura in childhood. Pediatr Blood Cancer 2009; 53:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol 2009; 61:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer KA. Coumarin-induced skin necrosis. Arch Dermatol 1993; 129:766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bovill EG, Bauer KA, Dickerman JD, et al. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arepally G, Cines DB. Heparin-induced thrombocytopenia and thrombosis. Clin Rev Allergy Immunol 1998; 16:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warkentin TE. Heparin-induced thrombocytopenia: a ten-year retrospective. Annu Rev Med 1999; 50:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980; 69:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li JY, Ivan D, Patel AB. Acral retiform purpura. Lancet 2017; 390:2382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saadoun D, Elalamy I, Ghillani-Dalbin P, et al. Cryofibrinogenemia: new insights into clinical and pathogenic features. Am J Med 2009; 122:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloch KJ, Maki DG. Hyperviscosity syndromes associated with immunoglobulin abnormalities. Semin Hematol 1973; 10:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane JE, Lane TN, Shams M, Lane CE. Cutaneous cholesterol embolization. J Am Acad Dermatol 2009; 60:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kusaba A, Imayama S, Furue M. Delayed appearance of livedo reticularis in 3 cases with a cholesterol embolism. Arch Dermatol 1999; 135:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aggarwal SK, Barik R, Sarma TC, et al. Clinical presentation and investigation findings in cardiac myxomas: new insights from the developing world. Am Heart J 2007; 154:1102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinede L, Duhaut P, Loire R. Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases. Medicine (Baltimore) 2001; 80:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callen JP. Cutaneous vasculitis: Relationship to systemic disease and therapy. Curr Probl Dermatol 1993; 5:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol 2006; 24:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol 2005; 27:504.
          </a>
         </li>
         <li class="breakAll">
          Della Rossa A, Tavoni A, Bombardieri S. Cryoglobulinemia. In: Rheumatology, 3rd ed, Hochberg M (Ed), Mosby, 2003. p.1697.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2002; 15:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalajian AH, Malhotra PS, Callen JP, Parker LP. Calciphylaxis with normal renal and parathyroid function: not as rare as previously believed. Arch Dermatol 2009; 145:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bobrowski AE, Langman CB. Hyperoxaluria and systemic oxalosis: current therapy and future directions. Expert Opin Pharmacother 2006; 7:1887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cochat P. Primary hyperoxaluria type 1. Kidney Int 1999; 55:2533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jorizzo JL. Livedoid vasculopathy: what is it? Arch Dermatol 1998; 134:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bard JW, Winkelmann RK. Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis. Arch Dermatol 1967; 96:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anavekar NS, Kelly R. Heterozygous prothrombin gene mutation associated with livedoid vasculopathy. Australas J Dermatol 2007; 48:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurwitz RM, Haseman JH. The evolution of pyoderma gangrenosum. A clinicopathologic correlation. Am J Dermatopathol 1993; 15:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jorizzo JL, Solomon AR, Zanolli MD, Leshin B. Neutrophilic vascular reactions. J Am Acad Dermatol 1988; 19:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Su WP, Davis MD, Weenig RH, et al. Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol 2004; 43:790.
          </a>
         </li>
         <li class="breakAll">
          Piette W. Purpura: mechanisms and differential diagnosis. In: Dermatology, 2nd ed, Bolognia JL, Jorizzo JL, Rapini RP (Eds), Elsevier Limited, 2008. Vol 1, p.321.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wysong A, Venkatesan P. An approach to the patient with retiform purpura. Dermatol Ther 2011; 24:151.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16556 Version 12.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31479689" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Retiform purpura: A diagnostic approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10451465" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Disseminated intravascular coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14871243" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Current understanding of disseminated intravascular coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14871243" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Current understanding of disseminated intravascular coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16507806" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Management of antiphospholipid antibody syndrome: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11953980" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16504826" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : New treatments for antiphospholipid syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8238072" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Early manifestation of thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19544391" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Thrombotic thrombocytopenic purpura in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19615543" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Warfarin-induced skin necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8507082" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Coumarin-induced skin necrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2521802" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The clinical spectrum of heterozygous protein C deficiency in a large New England kindred.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9773251" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Heparin-induced thrombocytopenia and thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10073268" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Heparin-induced thrombocytopenia: a ten-year retrospective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6996482" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28890159" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Acral retiform purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19958891" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cryofibrinogenemia: new insights into clinical and pathogenic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4633222" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Hyperviscosity syndromes associated with immunoglobulin abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19293029" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cutaneous cholesterol embolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10376714" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Delayed appearance of livedo reticularis in 3 cases with a cholesterol embolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18035082" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical presentation and investigation findings in cardiac myxomas: new insights from the developing world.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11388092" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical presentation of left atrial cardiac myxoma. A series of 112 consecutive cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cutaneous vasculitis: Relationship to systemic disease and therapy
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16966021" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Cutaneous vasculitis: diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16314707" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16314707" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12100455" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19380668" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Calciphylaxis with normal renal and parathyroid function: not as rare as previously believed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17020415" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hyperoxaluria and systemic oxalosis: current therapy and future directions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10354306" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Primary hyperoxaluria type 1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9554303" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Livedoid vasculopathy: what is it?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6054223" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Livedo vasculitis. Segmental hyalinizing vasculitis of the dermis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17535202" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Heterozygous prothrombin gene mutation associated with livedoid vasculopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8434729" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The evolution of pyoderma gangrenosum. A clinicopathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3060489" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Neutrophilic vascular reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15533059" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15533059" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21410606" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : An approach to the patient with retiform purpura.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
